Positive Results from First Clinical Study Evaluating A Clinical Target Presented at Major Scientific Meeting
Clinical study findings from two human skin studies using NPS technology were presented at the 2018 American Society for Laser Medicine and Surgery (ASLMS) in Dallas, TX on April 13, 2018. Taken together, these two studies are a foundation for designing future studies for the treatment of benign and non-benign lesions.
The first dose response study of NPS on human skin established an effective range of energy settings for which a unique cellular mechanism of action was observed and established a rationale for efficacy and safety for the treatment of epidermal lesions. ASLMS awarded this study with the Best of Basic Science and Translational Research Award.
The company's first clinical study evaluating NPS for the treatment of a benign skin condition, seborrheic keratosis lesions (SKs), demonstrated positive results for the removal of SK lesions with a single treatment of NPS technology, with a lesion clearance rate of 82% and no adverse events.